Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Machine Learning Identifies Candidates for Drug Repurposing in Alzheimer's Disease

PROVIDER: PRJNA691557 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13417900.fastq.gz	Fastqsanger.gz
	SRR13418000.fastq.gz	Fastqsanger.gz
	SRR13418100.fastq.gz	Fastqsanger.gz
	SRR13418200.fastq.gz	Fastqsanger.gz
	SRR13418300.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 765

Similar Datasets

Machine Learning Identifies Candidates for Drug Repurposing in Alzheimer's Disease

Project description:Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. In this study, we profile 80 FDA-approved and clinically tested drugs in neural cell cultures, with the goal of producing a ranked list of possible repurposing candidates.

2021-01-14 | GSE164788 | GEO

A Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules (ChIP-Seq)

Project description:High-throughput screening and gene signature analyses frequently identify lead therapeutic compounds with unknown modes of action (MoAs), and the resulting uncertainties can lead to the failure of clinical trials. We developed a multi-omics approach for uncovering MoAs through an interpretable machine learning model of the effects of compounds on transcriptomic, epigenomic, metabolomic, and proteomic data. We applied this approach to examine compounds with beneficial effects in models of Huntington’s disease, finding common MoAs for previously unrelated compounds that were not predicted based on similarities in the compounds’ structures, connectivity scores, or binding targets. We experimentally validated two such disease-relevant MoAs, autophagy activation and bioenergetics manipulation. This interpretable machine learning approach can be used to find and evaluate MoAs in future drug development efforts.

2020-01-22 | GSE129141 | GEO

Machine Learning Identifies Signatures of Macrophage Reactivity and Tolerance

Project description:Machine Learning Identifies Signatures of Macrophage Reactivity and Tolerance

| PRJNA839943 | ENA

Expression profiles of skeletal muscle from Taiwanese Smn-/-;SMN2 spinal muscular atrophy mouse model treated with Pip6a-PMO

Project description:Spinal muscular atrophy (SMA) is a neuromuscular disorder caused by loss of survival motor neuron (SMN) protein. While SMN restoration therapies are beneficial, they are not a cure. We aimed to identify novel treatments to alleviate muscle pathology combining transcriptomics, proteomics and perturbational datasets. This revealed potential drug candidates for repurposing in SMA. One of the candidates, harmine, was further investigated in cell and animal models, improving multiple disease phenotypes, including SMN expression and lifespan. Our work highlights the potential of multiple and parallel data driven approaches for the development of novel treatments for use in combination with SMN restoration therapies.

2020-05-14 | GSE150517 | GEO

A Multi-Omics Interpretable Machine Learning Model Reveals Modes of Action of Small Molecules (RNA-Seq)

2020-01-22 | GSE129143 | GEO

Methotrexate inhibition of SARS-CoV-2 entry, infection and inflammation revealed by bioinformatics approach and a hamster model

Project description:Drug repurposing is a fast and effective way to develop drugs for an emerging disease such as COVID-19. The main challenges of effective drug repurposing are the discoveries of the right therapeutic targets and the right drugs for combating the disease. Here, we present a systematic repurposing approach, combining Homopharma and hierarchal systems biology networks (HiSBiN), to predict 327 therapeutic targets and 21,233 drug-target interactions of 1,592 FDA drugs for COVID-19. Among these multi-target drugs, eight candidates (along with pimozide and valsartan) were tested and methotrexate was identified to affect 14 therapeutic targets suppressing SARS-CoV-2 entry, viral replication, and COVID-19 pathologies. Through the use of in vitro (EC50 = 0.4 uM) and in vivo models, we show that methotrexate is able to inhibit COVID-19 via multiple mechanisms. Our in vitro studies illustrate that methotrexate can suppress SARS-CoV-2 entry and replication by targeting furin and DHFR of the host, respectively. Additionally, methotrexate inhibits all four SARS-CoV-2 variants of concern. In a Syrian hamster model for COVID-19, methotrexate reduced virus replication, inflammation in the infected lungs. By analysis of transcriptomic analysis of collected samples from hamster lung, we uncovered that neutrophil infiltration and the pathways of innate immune response, adaptive immune response and thrombosis are modulated in the treated animals. We demonstrate that this systematic repurposing approach is potentially useful to identify pharmaceutical targets, multi-target drugs and regulated pathways for a complex disease. Our findings indicate that methotrexate is established as a promising drug against SARS-CoV-2 variants and can be used to treat lung damage and inflammation in COVID-19, warranting future evaluation in clinical trials.

2022-12-13 | GSE179709 | GEO

Whole transcriptome analysis of brain hippocampal tissue from SAMP8 mice and rat primary neurons treated with the Alzheimer's disease drug candidates CMS121 and J147

Project description:Alzheimer's disease (AD) drug discovery has rarely been addressed in the context of aging even though sporadic AD accounts for 99% of the cases. Phenotypic screens based upon old age-associated brain toxicities were used to develop the potent AD drug candidates CMS121 and J147. The aim of this project was to investigate whether these two different AD drug candidates prevented the progression of dementia in SAMP8 mice when administered at advanced stages of disease, and whether they shared common modes of action. These transcriptomic data are part of an integrative multi-omics approach that also investigated protein expression, metabolite levels as well as cognition. In addition, in order to further investigate the effect of the drugs in in vitro neuronal cultures, rat primary neurons were treated with the compounds and the transcriptome sequenced.

2019-11-26 | GSE101112 | GEO

undefined

Project description:Drug repurposing screen identifies lonafarnib as RSV fusion protein inhibitor

| PRJEB63686 | ENA

GNPS - PsA Disease Activity Chandran Lab

Project description:Classifying Patients with Psoriatic Arthritis According to their Disease Activity Status using Serum Metabolites and Machine Learning

2023-08-19 | MSV000092699 | GNPS

Project description:ABE-igRNA-machine learning

| PRJNA942901 | ENA